BE555319A - - Google Patents

Info

Publication number
BE555319A
BE555319A BE555319DA BE555319A BE 555319 A BE555319 A BE 555319A BE 555319D A BE555319D A BE 555319DA BE 555319 A BE555319 A BE 555319A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of BE555319A publication Critical patent/BE555319A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE555319D 1956-03-21 BE555319A (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US572788A US2868691A (en) 1956-03-21 1956-03-21 Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Publications (1)

Publication Number Publication Date
BE555319A true BE555319A (en:Method) 1900-01-01

Family

ID=24289356

Family Applications (1)

Application Number Title Priority Date Filing Date
BE555319D BE555319A (en:Method) 1956-03-21

Country Status (3)

Country Link
US (1) US2868691A (en:Method)
BE (1) BE555319A (en:Method)
GB (1) GB830426A (en:Method)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051621A (en) * 1959-10-22 1962-08-28 Grove Lab Inc Gel composition, pressurized container with same, and method of preparation
US3050443A (en) * 1960-02-16 1962-08-21 James F Schuyler Headache remedy containing ammonia
NL262354A (en:Method) * 1960-03-17
US3039928A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable aqueous isoproteronol compositions
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
BE632504A (en:Method) * 1962-05-24
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
NL302251A (en:Method) * 1963-01-28 1965-10-11
US3710782A (en) * 1969-10-01 1973-01-16 Hauser Res And Eng Co Method of treating human skin with a composition for electromedical applications
IL51314A (en) * 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
US4576949A (en) * 1984-05-07 1986-03-18 The Upjohn Company Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
EP0213108A3 (de) * 1985-06-26 1987-07-15 Kurt Dr. Burghart Pharmazeutische Zubereitung mit einem Antihypotonikum als wirksames Mittel
JPH0645538B2 (ja) * 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
FR2625677A1 (fr) * 1988-01-07 1989-07-13 Cosnier Alain Composition medicamenteuse destinee a etre administree sous forme d'aerosol
GB2216794B (en) * 1988-03-22 1991-11-20 Fisons Plc Pharmaceuticals compositions
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
NZ243062A (en) 1991-06-10 1993-09-27 Schering Corp Aerosol containing medicament and 1,1,1,2-tetrafluoroethane
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2125666C (en) * 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
CA2126244C (en) 1991-12-18 2000-09-26 Robert K. Schultz Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
RO117414B1 (ro) * 1992-12-09 2002-03-29 Jager Paul D Waterbury Compozitie farmaceutica de aerosol in solutie
ATE163006T1 (de) * 1993-06-01 1998-02-15 Ono Pharmaceutical Co Pentansäurederivate
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
CA2137106C (en) * 1993-12-03 2000-02-08 Hisao Nakai Amidinophenol derivatives
ES2145254T3 (es) * 1993-12-20 2000-07-01 Minnesota Mining & Mfg Formulaciones de aerosoles que contienen flunisolida.
KR100226619B1 (ko) 1994-09-20 1999-10-15 우에노 토시오 아미디노페놀 유도체
US5840213A (en) * 1995-04-28 1998-11-24 Great Lakes Chemical Corporation Uses of heptafluoropropane
US5679287A (en) * 1995-04-28 1997-10-21 Great Lakes Chemical Corporation Uses of heptafluoropropane
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
ATE226936T1 (de) * 1995-08-08 2002-11-15 Ono Pharmaceutical Co Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5861268A (en) * 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
JP2001511160A (ja) 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US7153866B1 (en) * 1997-05-27 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JPH11187882A (ja) 1997-12-26 1999-07-13 Ono Pharmaceut Co Ltd 新規なポリペプチド、その製造方法、そのポリペプチドをコードするcDNA、そのcDNAからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
PT1417975E (pt) 2001-07-23 2011-05-30 Ono Pharmaceutical Co Medicamentos que cont?m um agonista de ep4 como princ?pio activo destinados a doen?as associadas a perda de massa ?ssea
JP3843454B2 (ja) 2002-02-19 2006-11-08 小野薬品工業株式会社 縮合ピリダジン誘導体化合物およびその化合物を有効成分として含有する薬剤
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
EP2266533A3 (en) * 2002-06-25 2011-12-14 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
EP1522314B1 (en) 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
AU2003241836A1 (en) 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
JPWO2004032964A1 (ja) * 2002-10-10 2006-02-09 国立大学法人京都大学 アレルギー性疾患治療剤
PT2465537T (pt) 2002-10-10 2016-08-03 Ono Pharmaceutical Co Microsferas compreendendo ono-1301
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
AU2004240629B2 (en) * 2003-05-16 2010-02-25 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
WO2006031210A1 (en) 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
JP4666257B2 (ja) 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
ES2754221T3 (es) 2003-08-29 2020-04-16 Ono Pharmaceutical Co Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo
MXPA06002152A (es) 2003-09-01 2006-05-22 Ono Pharmaceutical Co Compuesto de anillo condensado y uso del mismo.
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
BRPI0415707A (pt) * 2003-10-20 2006-12-19 Schering Corp composições farmacêuticas
WO2005063704A1 (ja) 2003-12-25 2005-07-14 Ono Pharmaceutical Co., Ltd. アゼチジン環化合物およびその医薬
US20060018840A1 (en) * 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
EP1806147B1 (en) 2004-10-21 2014-04-30 Ono Pharmaceutical Co., Ltd. Use of immunesuppressant receptor
ES2331619T3 (es) * 2004-11-24 2010-01-11 Alcon, Inc. Procedimiento de administracion de spray nasal.
US8563581B2 (en) 2005-02-02 2013-10-22 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating predisposed or at risk patients
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
DK2594272T3 (en) 2005-05-18 2018-09-03 Horizon Orphan Llc Aerosolized fluoroquinolones and their applications
ES2675228T3 (es) * 2005-06-17 2018-07-09 Wisconsin Alumni Research Foundation Preparaciones tópicas de vasoconstrictores y métodos para proteger a las células durante la quimioterapia y radioterapia del cáncer
WO2007049771A1 (ja) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2007069565A1 (ja) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
EP1961754A4 (en) 2005-12-15 2009-11-11 Ono Pharmaceutical Co BICYCLIC HETEROCYCLIC COMPOUND
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
MX2009008582A (es) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
KR20160150110A (ko) 2008-10-07 2016-12-28 랩터 파마슈티컬스 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
US8629139B2 (en) * 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
ES2511065T3 (es) 2009-06-17 2014-10-22 Ono Pharmaceutical Co., Ltd. Nuevo compuesto imidazopiridina
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
LT2473170T (lt) 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
US8598223B2 (en) 2010-06-21 2013-12-03 Ono Pharmaceutical Co., Ltd. Crystalline forms of 4, 4′-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4′-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4′-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid
TWI534125B (zh) 2010-12-02 2016-05-21 Ono Pharmaceutical Co Novel compounds, salts thereof or solvates thereof, and pharmaceutical compositions and pharmaceutical products containing the same
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9353113B2 (en) 2011-03-18 2016-05-31 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
JP6160613B2 (ja) 2012-04-26 2017-07-12 小野薬品工業株式会社 Trk阻害化合物
MX353336B (es) 2013-02-19 2018-01-09 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10016439B2 (en) 2014-01-31 2018-07-10 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
US20210000830A1 (en) 2017-09-06 2021-01-07 Ono Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD USING Trk INHIBITOR AND KINASE INHIBITOR IN COMBINATION
WO2019230919A1 (ja) 2018-05-31 2019-12-05 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Sting促效化合物
JP7662156B2 (ja) 2019-08-05 2025-04-15 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
TW202134213A (zh) 2019-11-29 2021-09-16 日商小野藥品工業股份有限公司 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
WO2021159077A1 (en) 2020-02-07 2021-08-12 Case Western Reserve University Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
JPWO2021205631A1 (en:Method) 2020-04-10 2021-10-14
CA3182959A1 (en) 2020-05-12 2021-11-18 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2022251679A1 (en) 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222976A (en) * 1937-11-15 1940-11-26 Sharp & Dohme Inc Nasal drops
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor

Also Published As

Publication number Publication date
GB830426A (en) 1960-03-16
US2868691A (en) 1959-01-13

Similar Documents

Publication Publication Date Title
AT11375B (en:Method)
AT13049B (en:Method)
AT11620B (en:Method)
AT12270B (en:Method)
AT12073B (en:Method)
DE7622443U1 (en:Method)
AT12626B (en:Method)
AT12140B (en:Method)
AT2094B (en:Method)
AT13632B (en:Method)
AT11596B (en:Method)
AT2192B (en:Method)
AT2342B (en:Method)
AT11591B (en:Method)
AT11588B (en:Method)
AT11578B (en:Method)
AT11483B (en:Method)
AT11438B (en:Method)
AT2432B (en:Method)
AT11404B (en:Method)
AT2478B (en:Method)
AT10906B (en:Method)
AT12867B (en:Method)
AT10783B (en:Method)
AT11927B (en:Method)